Structural polymorphism of paraoxonase gene as a risk factor of myocardial infarction in men under 45

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The enzyme paraoxonase (PON1) is associated with high density lipoproteins. It plays an important role in preventing low density lipoprotein oxidation and thus may be involved in protection against atherosclerosis. This study was conducted to estimate the genotype distributions of the C(-108)T polymorphism in the promoter region of the PON1 gene, the L54M and Q191R polymorphisms of its coding region in men, survived after myocardial infarction (Ml) at the age of 45 (206 subjects) and in control group (177 subjects). The R191 allele frequency was significantly higher in patients than in controls (p<0,0003). Odds ratio (OR) for the RR genotype carriers was 3,8. The C(-108) allele frequency was statistically increased among controls compared with patients (p<0,05). OR for the high expressor CC genotype carriers was 0,6. No significant association was found between L54M and Ml. Thus, the RR191 PON1 genotype could be considered as a risk factor for Ml in men under 45 years old and the CC(-108) genotype as a protective factor for the disease.

About the authors

S. N. Ptchelina

Institute of Nuclear Physics RAS; I. P. Pavlov State Medical University

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 188350; St. Petersburg, 197089

S. V. Kudinov

Institute of Nuclear Physics RAS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 188350

O. A. Berkovitch

I. P. Pavlov State Medical University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 197089

E. A. Bazhenova

I. P. Pavlov State Medical University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 197089

D. V. Tcherkashin

Russian Military-Medical Academy

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 194175

E. V. Shlyakhto

I. P. Pavlov State Medical University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 197089

S. A. Boytsov

Russian Military-Medical Academy

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 194175

A. D. Denisenko

Institute of Experimental Medicine PAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 197376

E. I. Shwartz

Institute of Nuclear Physics RAS; I. P. Pavlov State Medical University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 188350; St. Petersburg, 197089

References

  1. Akhmedova S., Anisimov S., Yakimovsky A., Schwartz E. Gln-Arg191 polymorphism of paraoxonase and Parkinson’s disease // Human Heredity. 1999. Vol. 49. P. 178-180.
  2. Akhmedova S., Yakimovsky A., Schwartz E. Paraoxonase 1 Polymorphism Met-Leu 54 Is Associated with Parkinson’s Disease // J. Neurol. Sciences. 2001. Vol. 184. P. 179-182.
  3. Blatter Garin M. C., James R. W., Dussoix P. et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme // J. Clin. Invest. 1997. Vol. 99. P. 62-66.
  4. Brophy V. H., Hastings M. D., Clendenning J. B. et al. Polymorphisms in the human paraoxonase (PON1) promoter // Pharmacogenetics. 2001. Vol. 11. P. 77-84.
  5. Davies H. G., Richter R. J, Keifer M. et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin //Nat. Genet. 1996. Vol. 14. P. 334-336.
  6. Durrington P. N., Mackness B., Mackness M. I. Paraoxonase and atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2001. Vol. 21. P. 473-480.
  7. Ferre N., Camps J., Prats E. et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage // Clin. Chern. 2002. Vol. 48. P. 261-268.
  8. Gardemann A., Philipp M., Hess K. et al. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease // Atherosclerosis. 2000. Vol. 152. P. 421-431.
  9. Herrmann S. M., Blanc H., Poirier O. et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study // Atherosclerosis. 1996. Vol. 126. P. 299-304.
  10. Humbert R., Adler D. A., Disteche С. M. et al. The molecular basis of human serum paraoxonase activity polymorphism // Nat. Genet. 1993. Vol. 3. P. 73-76.
  11. Imai Y, Morita H., Kurihara H. et al. Evidence for association between paraoxonase gene plymorphisms and atherosclerotic diseases // Atherosclerosis. 2000. Vol. 149. P. 43 5-442.
  12. Klimov A. N., Gurevich V. S., Nikiforova A. A. et al. Antioxidative activity of high-density lipoproteins in vitro // Atherosclerosis. 1993. Vol. 100. P. 13-18.
  13. Ko Y-L., Ko Y-S., Wang S-M. et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan // Atherosclerosis. 1998. Vol. 141. P. 259-264.
  14. Leviev L, James R. W. Promoter polymorphisms of human paraoxonase PON 1 gene and serum paraoxonase activities and concentrations // Arterioscler. Thromb. Vasc. Biol. 2000. Vol. 20. P. 516-521.
  15. Leviev L., Poirier O., Nicaud V. et al. High expressor paraoxonase PON 1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients // Atherosclerosis. 2002. Vol. 161. P. 463-467.
  16. Leviev L., Righetti A., James R. W. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease // J. Mol. Med. 2001. Vol. 79. P. 457-463.
  17. Mackness B., Davies G. K, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype // Arterioscler. Throm. Vasc. Biol. 2001. Vol. 21. P. 1451-1457.
  18. Mackness B., Durrington P. N., Mackness M. I. Human serum paraoxonase // Gen. Pharmac. 1998. Vol. 31. P. 329-336.
  19. Mackness B., Machness M. L, Arrol S. et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus // Atherosclerosis. 1998. Vol. 139. P. 341-349.
  20. Mackness M. L, Arrol S., Mackness B., Durrington P N. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation // Lancet. 1997. Vol. 349. P. 851-852.
  21. Oda M. N, Bielicki J. К, Ho T. T. et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins // Biochem. Biophys. Res. Commun. 2002. Vol. 290. P. 921-927.
  22. Ombers D., Pannitteri G., Mantali A. et al. The Gin-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients // Arterioscler. Thromb. Vasc. Biol. 1998. Vol. 18. P. 1611-1616.
  23. Pfohl M., Koch M., Enderle M. D. et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, myocardial infarction in type 2 diabetes // Diabetes. 1999. Vol. 48. P. 623-627.
  24. Ruiz J., Blanche H., James R. W. et al. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes // Lancet. 1995. Vol. 346. P. 869-872.
  25. Salonen J. T., Malin R., Tuomainen P. et al. Polymorphism in high-density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study // British Med. Journ. 1999. Vol. 319. P. 487-489.
  26. Sanghera D. K., Saha N, Aston С. E., Kamboh M. L Genetic polymorphism of paraoxonase and the risk of coronary heart disease // Arterioscler. Throm. Vasc. Biol. 1997. Vol. 17. P. 1067-1073.
  27. Schmidt H., Schmidt R., Niederkorn K. et al. Paraoxonase PON 1 Polymorphism Leu-Met54 is associated with carotid atherosclerosis // Stroke. 1998. Vol. 29. P. 2043-2048.
  28. Sen-Banerjee S., Siles X., Campos H. Tobacco smoking modifies association between Gln-Arg 192 polymorphism of human paraoxonase gene and risk of myocardial infarction // Arterioscler. Thromb. Vasc. Biol. 2000. Vol. 20. P. 2120-2126.
  29. Senti M., Aubo C., Tomas M. Differential effects of smoking on myocardial infarction risk according the Gln/Arg variants of the human paraoxonase gene // Metabolism. 2000. Vol. 49. P. 557-559.
  30. Senti M., Tomas M., Marrugat J., Elosua R., for the REGICOR investigators. Paraoxonase 1 - 192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs // Arterioscler. Thromb. Vasc. Biol. 2001. Vol. 21. P. 415-420.
  31. Senti M., Tomas M., Vila J. et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase 1 gene: the REGICOR study // Atheriosclerosis. 2001. Vol. 15 6. P. 443-449.
  32. Shih D. M., Gu L., Xia Y-R. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis // Nature. 1998. Vol. 394. P. 284-287.
  33. Suehiro T., Nakamura T., Inoue M. et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression // Atherosclerosis. 2000. Vol. 150. P. 295-298.
  34. Zama T., Murata M., Matsubara Y. et al. A 192- Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese // Arterioscler. Tromb. Vasc. Biol. 1997. Vol. 17. P. 3565-3569.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.